TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM

DIATRIZOATE MEGLUMINE
Gastroenterology Approved 2022-06-27
2
Indications
--
Phase 3 Trials
3
Years on Market

Details

Status
Prescription
First Approved
2022-06-27
Routes
ORAL, RECTAL
Dosage Forms
SOLUTION

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM Approval History

Loading approval history...

What DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM Treats

1 indications

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM is approved for 1 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Esophagus Disease
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM FDA Label Details

Pro

Indications & Usage

Diatrizoate meglumine and diatrizoate sodium solution is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. Diatrizoate meglumine and diatrizoate sodium solution may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration ...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.